Literature DB >> 10088997

The role of integrins in immune-mediated diseases of the nervous system.

J J Archelos1, S C Previtali, H P Hartung.   

Abstract

Immune-mediated diseases of the CNS and PNS, such as multiple sclerosis and Guillain-Barré syndrome, respectively, constitute a major cause of transient and permanent neurological disability in the adult. The aetiology and pathogenesis of these disorders are only partially understood. On a cellular level, focal mononuclear-cell infiltration with demyelination and eventual axonal loss is a crucial pathogenetic event that leads to inflammation and subsequent dysfunction. Here, the evidence that integrins, a family of cell adhesion molecules, expressed on neural and immune cells might play a central role in immune cell recruitment to the CNS and PNS, and probably in tissue repair is reviewed. Distinct integrin expression patterns are observed in multiple sclerosis and Guillain-Barré syndrome. Therapeutic targeting of integrins has been very successful in the corresponding animal models and holds promise as a novel treatment strategy to combat human immune-mediated disorders of the nervous system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10088997     DOI: 10.1016/s0166-2236(98)01287-9

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  27 in total

1.  Regulation of an inactivating potassium current (IA) by the extracellular matrix protein vitronectin in embryonic mouse hippocampal neurones.

Authors:  Dmitry V Vasilyev; Michael E Barish
Journal:  J Physiol       Date:  2003-01-24       Impact factor: 5.182

Review 2.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

3.  Disruption of the beta2-integrin CD11d (alphaDbeta2) gene fails to protect against experimental autoimmune encephalomyelitis.

Authors:  Jillian E Adams; Matthew S Webb; Xianchen Hu; Don Staunton; Scott R Barnum
Journal:  J Neuroimmunol       Date:  2007-01-23       Impact factor: 3.478

4.  Rapid identification of fluorochrome modification sites in proteins by LC ESI-Q-TOF mass spectrometry.

Authors:  Prakash Manikwar; Tahl Zimmerman; Francisco J Blanco; Todd D Williams; Teruna J Siahaan
Journal:  Bioconjug Chem       Date:  2011-06-07       Impact factor: 4.774

Review 5.  Targeting the blood-nerve barrier for the management of immune-mediated peripheral neuropathies.

Authors:  Evan B Stubbs
Journal:  Exp Neurol       Date:  2020-06-17       Impact factor: 5.330

Review 6.  beta2-integrins in demyelinating disease: not adhering to the paradigm.

Authors:  Xianzhen Hu; Jillian E Wohler; Kari J Dugger; Scott R Barnum
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

Review 7.  [Multiple sclerosis: potential therapeutic options and update of ongoing studies].

Authors:  H Wiendl; H C Lehmann; R Hohlfeld; H-P Hartung; B C Kieseier
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

8.  Models of autoimmune demyelination in the central nervous system: on the way to translational medicine.

Authors:  Ralf A Linker; De-Hyung Lee
Journal:  Exp Transl Stroke Med       Date:  2009-10-21

9.  Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.

Authors:  Sebastian Doerck; Kerstin Göbel; Gesa Weise; Tilman Schneider-Hohendorf; Michael Reinhardt; Peter Hauff; Nicholas Schwab; Ralf Linker; Mathias Mäurer; Sven G Meuth; Heinz Wiendl
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

10.  B cells and monocytes from patients with active multiple sclerosis exhibit increased surface expression of both HERV-H Env and HERV-W Env, accompanied by increased seroreactivity.

Authors:  Tomasz Brudek; Tove Christensen; Lars Aagaard; Thor Petersen; Hans J Hansen; Anné Møller-Larsen
Journal:  Retrovirology       Date:  2009-11-16       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.